Four Orphan Drugs Cleared For Europe Could Strain Health Budgets
This article was originally published in The Pink Sheet Daily
Executive Summary
The Committee for Medicinal Products for Human Use gave positive opinions on Alexion’s enzyme replacement therapies asfotase alfa and sebelipase alfa, Novartis’ HDAC inhibitor panobinostat and Santhera’s idebenone during its June meeting, a move likely to strain the budgets of Europe’s health care payers in the months to come.